|
Originally published In Press as doi:10.1074/jbc.M000382200 on July 13, 2000
J. Biol. Chem., Vol. 275, Issue 40, 31379-31386, October 6, 2000
COT Kinase Proto-oncogene Expression in T Cells
IMPLICATION OF THE JNK/SAPK SIGNAL TRANSDUCTION PATHWAY IN
COT PROMOTER ACTIVATION*
Estrella
Sánchez-Góngora ,
Carlos
Lisbona ,
Rosa
de
Gregorio,
Alicia
Ballester,
Victor
Calvo,
Luis
Pérez-Jurado§, and
Susana
Alemany¶
From the Instituto de Investigaciones Biomedicas, Consejo Superior
de Investigaciones Científicas, Facultad Medicina Universidad
Autonoma de Madrid, Arturo Duperier 4, 28029 Madrid and
§ Servicio de Genética, Hospital Universitario LA
PAZ, 28046 Madrid, Spain
Received for publication, January 19, 2000, and in revised form, July 10, 2000
 |
ABSTRACT |
COT/Tpl-2 proto-oncogene encodes a
serine/threonine kinase implicated in cellular activation. In this
study we have identified the human COT gene promoter region
and three different human COT transcripts. These
transcripts, with the same initiation site, display
heterogeneity in their 5' untranslated regions and in their subcellular
localization. Activation of Jurkat T cells with either calcium
ionophore A23187 or CD3 and a phorbol ester increases the levels of
the different COT transcripts. Analysis of the 5' flanking
region of the human COT gene reveals a unique transcription
initiation site and a TATA element 20 nucleotides upstream.
Transient expression of COT promoter constructs containing a reporter gene indicates that the transcriptional activity of the 5'
flanking region of the COT gene is regulated by T
cell-activating signals. Cotransfection of a dominant negative
version of SEK-2 abolishes the inducible transcriptional activity of
COT promoter, indicating that the inducible expression of
the COT gene by T cell activating signals is mediated by
the JNK/SAPK signal transduction pathway. All these data indicate
stringent regulation of COT kinase proto-oncogene expression.
 |
INTRODUCTION |
COT/Tpl-2 is homologous to members of the mitogen-activated
protein kinase kinase kinase family (MAP3K) and has been
implicated in cellular activation (1-5). Overexpression of COT/Tpl-2
induces activation of MEK-11
and SEK-1 kinases, activating the ERK and JNK/SAPK signal transduction pathways, respectively (1, 6, 7). COT/Tpl-2 kinase regulates the
transcription of tumor necrosis factor and interleukin 2 genes during T cell activation (8, 9) by activating at least AP-1 and
NF- B response elements in the gene promoters
(9-13).
Several COT/Tpl-2 cDNAs comprising the complete coding sequence and
3' UTR have been reported: two different human cDNAs
(GenBankTM accession numbers Z14138 and D14497) (14,
15), two rat cDNAs (GenBankTM accession numbers M94454
and L15358) (16), and one murine COT cDNA
(GenBankTM accession number D13759) (17). Identities
between human, rat, and murine COT cDNAs in their coding
sequences and 3' UTRs are 85 and 75%, respectively. The 5' UTR of the
human, rat, and murine COT cDNAs did not reveal any
homology, with the exception of the 23 nt upstream from the first
COT/Tpl-2 ATG codon.
The human COT gene is a single copy locus (14, 18) localized
on the short arm of chromosome 10 at band p11.2 (14). Ohara et
al. (17) proposed that the human COT gene contains nine
exons, of which the last seven are coding exons. COT kinase was first identified in a truncated form in transformed foci induced in SHOK cells by transfection of the genomic DNA of a human thyroid carcinoma cell line (18, 19). This rearrangement occurs in the
penultimate coding exon and provides transformation capacity (15). The
rat homologue of the human COT gene (Tpl-2) was identified as an oncogene associated with the progression of Moloney murine leukemia virus-induced T cell lymphomas in rats (4, 16). As with the
human and murine homologues, the disruption of the last coding exon of
Tpl-2 by insertion of the Moloney murine leukemia virus enhances
mRNA levels and appears to unmask the oncogenic potential of the
protein (4, 15, 20, 21). It has been suggested recently that an
amplification of the genomic locus of the COT gene plays a
role in human breast cancer (22).
In this paper we have studied the expression of the human
COT gene in T cells. We have identified three different
human COT mRNAs and the 5' region flanking the
transcription initiation site of the COT gene. We also
provide evidence that T cell activation up-regulates the levels of the
three COT kinase mRNAs and increases the transcriptional activity
of the human COT gene promoter through the JNK/SAPK signal
transduction pathway.
 |
EXPERIMENTAL PROCEDURES |
Primers--
Primers located 3' from the transcription
initiation site of the COT gene (+1 nt) have been designated
according to their location in COT-1 cDNA: 8D
( 1082/ 1060 nt), 5'-CTGCA AAAATAAGTGAAAGTGAC; 7D ( 778/ 758 nt),
5'-GCTTTCATCAGGTTGACTGATGTCA; 6D ( 723/ 704 nt),
5'-AGAAGGATTCAGAGGTCAGA; 5D ( 650/ 631 nt),
5'-TTGGGGAGTTTTTCTAACTC; 4D ( 66/ 448 nt), 5'-GGGATGGAGAGGTAAGCAT;
3D ( 340/ 318 nt), 5'-ATTGTGCAGACAT TGATTCATTT; 2D
( 229/ 210 nt), 5'-CTCCACCATATGATTCTAAT; 1D ( 102/ 83 nt),
5'-AGCT TGGCAAAACTTCTTCA; 1D (122/141 nt), 5'-CCAGCATCGCACCGAAACCTT; 2D
(589/609 nt), 5'-CCCGATCCTCCCAAATGCTGG; 3D (107/1090 nt),
5'-CCTGAGTCGTTTGTGCCAAG; 4D (1731/1752 nt), 5'-CATTTTCATTCACACTTGCCAG;
5D (2237/2256 nt), 5'-TCAGCGTCAGACACTCCTCC; 6D (2989/3008 nt),
5'-ATCTTCTTACCGCGAAGAAG; 7D (3984/4003 nt), 5'-CAAGATGTTTGCTTTGCACTA;
8D (4643/4662 nt), 5'-CCAATCCTTGTATGTCAGTT; 9D (4749/4769 nt),
5'-ATGGAGTACATGAGCACTGGA; UpTATA ( 49/ 30 nt), 5'-CTTCTTGTCACATAGCCCAG; PR (98/115 nt), 5'-GCCTGTGGGAGCCGAGCA; PE
(123/140 nt), 5'-AGGTTCGGTGCGATGCTG; 1R (588/607 nt),
5'-AGCATTTGGGAGGATCGGGT; 2R (1070/1090 nt), 5'-CTTGGCACAAACGACTCAGGC;
3R (1731/1752 nt), 5'-CTGGCAAGTGTGAATGAAAATG; 4R (2762/2784 nt),
5'-ATTTGACTTCGGTTTTACTGAGC; 5R (3006/3033 nt),
5'-AAGATGTGGCTACCTATTCCCCTGGCTT; 6R (3767/3790 nt),
5'-GAGTAACAACGTCAGTTTTTACCC; 7R (4932/4951 nt),
5'-TTGGCCACTAAGCAGCAGAG; 8R (5133/5152 nt), 5'-GAGAACATCGGAATCTATT; 9R
(6206/6229 nt), 5'-GGCCCCTGTGTAGAGGCAGCAGAA; 5' -actin,
5'AGCACAATGAAGATCAAGAT; and 3' -actin, 5'TGTAACGCAACTAAGTCATA.
DNA Isolation and COT Promoter-Luciferase Reporter Vector
Constructs--
Genomic DNA was obtained as described previously (23).
A 6.1-kb DNA fragment containing the 5' region flanking the translation initiation site of COT kinase was obtained with the human genomic DNA
PromoterFinderTM DNA walking kit
(CLONTECH), using two specific reverse primers deduced from the sequence of the first COT coding exon.
Different DNA fragments of the 5' flanking region of the COT
gene were generated by PCR with different direct primers ( 8D, 7D,
6D, 5D, 4D, 3D, 2D, and 1D) and PR as reverse primer. The
778 PCR product was performed with 7D and upTATA primers.
Purified PCR products were cloned in pMOS Blue T-vector (Amersham
Pharmacia Biotech). Single clones were selected, and their
sequences were compared with the original template. From these
constructs, the KpnI/HindIII fragments were
cloned in the pGL3-Basic Luc-reporter vector (Promega). Sequencing,
using specific oligonucleotides and Sequenase (U. S. Biochemical
Corp.), was performed by the Sanger method (24). Gene Jockey II,
DNAstrider 1.1, MacPattern Folder, and Blast programs were used to
analyze the DNA sequences.
Cells, Transient Transfection Analysis, and Polysome
Gradients--
Human leukemia T Jurkat cells were electroporated as
previosuly described (9) with 20 µg of the different pGL3-Luc
constructs. After a 2-h incubation, cells were stimulated for 12 h
with different stimuli: soluble CD3 (10 µg/ml, obtained as
indicated in Ref. 9), calcium ionophore A23187 (0.25 µM,
Sigma), and/or PDBu (50 ng/ml, Roche Molecular Biochemicals).
Cyclosporin A (100 ng/ml), 8-Br-cAMP (0.5 mM, Roche
Molecular Biochemicals), PD 98059 (MEK inhibitor) (20 µg/ml,
Calbiochem), or SB-20580 (HOG/p38 mitogen-activated protein kinase
inhibitor) (20 µg/ml, SmithKline Beecham), and/or okadaic acid
(100 ng/ml, Calbiochem) were added 30 min before stimulation. Luciferase activity and protein concentration were measured as described previously (9).
To perform the polysome fractionation, 8 × 107 cells
were lysed as described previously (25) and centrifuged at 10,000 × g for 10 min at 4 °C. The supernatant was spun in a
10-50% linear sucrose gradient buffered with 20 mM HEPES
(pH 7.3), 250 mM KCl, 20 mM MgCl2,
2 mM dithiothreitol, and 500 µg/ml heparin at 36,000 rpm
for 2 h at 4 °C in a SW 41 rotor (Beckman). Fractions of 1 ml
were collected, and ethanol was precipitated. RNA was extracted from
the pellets by using the SV total RNA isolation system kit (Promega).
Northern Blot and Dot Blot Analysis--
By using Ultraspec
(Biotecx Laboratories), 20 µg of total RNA was extracted from
Jurkat cells stimulated with 50 ng/ml PDBu, 0.25 µM
calcium ionophore, and 100 nM okadaic acid for
different times. RNA was electrophoresed and blotted onto a nylon
membrane (Nytran, NY 13N, Renner GmbH). Filters were hybridized with a random primer-labeled cDNA (>109 cpm/µg) comprising
the entire human COT open reading frame (14). Membranes were
exposed to x-ray film for 10 days at 70 °C.
Multiple tissue human poly(A)+ RNA Northern blot
(CLONTECH) was hybridized with different probes as
described above. Stripping was performed by boiling the membrane
for 30 min in 0.1 × SSC and 0.5% SDS. Control autoradiographs
were performed after each stripping.
Dot blots performed with total RNA and RNA isolated from different
subcellular fractions (25) were hybridized with the COT coding probe, with probe C (3837-4646 nt), and with the COT
promoter probe ( 778 to 30 nt). The autoradiograph was exposed for 7 days at 70 °C.
RT-PCR and Primer Extension Assays--
Two µg of total RNA
treated with 2.5 units of DNase I (Life Technologies, Inc.) as in Ref.
9 were subjected to the RT reaction (9). One µl of this reaction was
used for PCR analysis. Control samples treated with DNase I and not
exposed to RT were also subjected to PCR. To perform the RT-PCRs from
leukocyte mRNA, 1 µl of human leukocyte Marathon-ready cDNA
library (CLONTECH) was used. Controls without a
template, with genomic DNA as a template, and with one single primer
were performed.
Seven pmol of the 5'-end-labeled oligonucleotide PE, complementary to
nt 123-140 of the three COT transcripts, was annealed to 7 µg of poly(A)+ RNA from PDBu- and calcium
ionophore-stimulated Jurkat cells, and a RT reaction was carried out.
After synthesis, nucleic acids were precipitated, and reaction products
were analyzed on 6% polyacrylamide gels containing 8 M urea.
RNase Protection and S1 Nuclease Protection Assays--
A 434-nt
labeled RNA probe (50-80 × 104 cpm/fmol), of which
409 nt were complementary to nt 5820-6229 of COT-1
that corresponds to a region of the coding sequence, was obtained using
the Maxiscript kit (Ambion). RNase A protection assay was performed
with the radioimmune precipitation buffer II kit (Ambion). Dried gels
were exposed to x-ray films at 70 °C for 2 days. For the S1
nuclease analysis a radiolabeled DNA probe (probe D (589-2784 nt),
10-30 × 105 cpm/fmol) was obtained using the
Prime-A-Probe kit (Ambion) according to the manufacturer's
instructions, except that 0.9% alkaline agarose gels were used to
purify the labeled probe. Nuclease S1 protection assay was performed
with the Multi-NPA kit (Ambion). Agarose gels (0.9%) were
exposed to x-ray films at 70 °C for 4 days.
 |
RESULTS |
Identification of Three Human COT Transcripts--
Hybridization
of a leukocyte poly(A)+ RNA Northern blot with a coding
COT probe yielded two hybridization signals at 3.0 and 7.3 kb (Fig. 1A). To investigate
whether the occurrence of these transcripts was due to the different
length of the 5' UTR, we cloned and sequenced a 6.1-kb DNA genomic
fragment containing the 5' flanking region of the COT
translation initiation site. Several probes from this region were
generated by PCR (Fig. 1A). Analysis of the
poly(A)+ RNA Northern blot with these probes revealed a
hybridization signal only at 7.3 kb (Fig. 1A), indicating
that this COT mRNA species has a large 5' UTR.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 1.
Identification of three COT
transcripts. A, human leukocyte
poly(A)+ RNA Northern blot was hybridized with the coding
sequence of COT kinase and with three different probes from the 5'
flanking region of the COT translation initiation site. A
schematic representation of the localization of these probes in the
genomic DNA fragment is also shown. According to the numbering given to
the sequence of the COT-1 transcript, probe A corresponds to
nt 290-608, probe B to nt 2234-2784, and probe C to nt 3837-4646.
These probes were generated by PCR. The coding COT probe was
generated by PCR with primers 9D and 9R and reverse transcribed
mRNA from Jurkat cells as a template. B, PCRs from
cDNA of Jurkat cells were performed with the indicated primers.
Diagrams show the positions of the primers in the different human
COT cDNAs. M, molecular weight
markers. C, S1 nuclease protection analysis of
COT-1 mRNA in Jurkat cells with probe D (nt 589-2784).
RNAs (30 µg) from Jurkat T lymphocytes (T) or yeast
(Y) were used. Undigested probe (U.P.) was also
electrophoresed. D, relative levels of
COT-1/COT-2 and COT-2/COT-3
transcripts were measured by RT-PCR in different human tissues.
Lanes: 1, liver; 2, pancreas;
3, muscle; 4, peripheral blood
leukocytes; 5, lung; and 6, kidney.
Relative levels of COT-1/COT-2 were determined
using the primers 6D (0.5 µM), 8D (0.5 µM),
and 8R (1 µM). The 630- and 565-bp PCR products
correspond to COT-2 and COT-1 transcripts,
respectively. Relative levels of COT-2/COT-3
transcripts were detected with primers 1D (0.5 µM), 6D
(0.5 µM), and 7R (1 µM). The 527- and
299-bp PCR products correspond to COT-2 and
COT-3, respectively.
|
|
To determine the sequence of the 5' UTR of the different COT
mRNAs, RT-PCR analysis was performed. The direct and reverse primers used were deduced from the sequence of the 6.1-kb genomic fragment containing the 5' flanking region of the COT
translation initiation site. PCR of overlapping fragments was performed
using as a template reverse transcribed mRNA of Jurkat cells.
Different PCRs were performed with the combinations of each direct
primer and all the different 3'-located reverse primers. Control
samples treated with DNase I and not exposed to RT were also subjected to PCR. Controls without a template, with genomic DNA as a template, and with one single primer were also performed. The different PCR
products obtained (Fig. 1B) were analyzed by restriction
mapping and by sequencing (data not shown). The same overlapping PCR
products were obtained when human leukocyte cDNA was used as a
template (data not shown). This analysis revealed that the
COT gene is transcribed with three different 5' UTRs. The
transcription start site of these three 5' UTRs was delimited to the
same 30-nt region by PCR analysis, using as a template cDNA from
Jurkat cells as well as human leukocyte cDNA (data not shown). (See
"Determination of the Transcription Start Site of the Human COT
Gene" for the location of the exact start transcription site.)
To establish the 5' UTR of COT-1 by a method other
than RT-PCR, S1 nuclease analysis was performed. A DNA probe (probe D)
complementary to the 589-2784-nt sequence of the 5' UTR of
COT-1 was hybridized with RNA obtained from Jurkat
cells and incubated with nuclease S1 (Fig. 1C). This probe
contains the entire sequence of probe B and is extended to the DNA
sequence of probe A. The intron/exon boundaries of the three different
5' UTRs of COT transcripts are shown in Table
I.
View this table:
[in this window]
[in a new window]
|
Table I
Intron-exon organization of the 5' region of the human COT gene
Positions have been designated according to their location in the COT-1
transcript. Exon sequences are shown in uppercase letters; intron
sequences are shown in lowercase letters.
|
|
We also investigated the possibility of alternative splicing in the
coding sequence and 3' UTR of COT transcripts. RT-PCR analysis revealed no alternative splicing in these regions. The coding
sequence and 3' UTR region of COT transcripts have a size of
2.5 kb (data not shown). Considering the length of the 5' UTR of
the three COT transcripts, the 7.3-kb COT
mRNA species detected in the leukocyte poly(A)+ RNA
Northern blot (Fig. 1A) should correspond to
COT-1, and the 3.0-kb signal should correspond to
COT-2 and COT-3. The three COT
transcripts were detected by RT-PCR in all human tissues tested (Fig.
1D), indicating that none of the different COT
transcripts is tissue-specific, although the relative amounts seem to
vary between the different tissues. When the PCRs were performed as described in the legend to Fig. 1D, the ratio of
COT-2 to COT-1 oscillated between 0.5 for
liver or pancreas and 1.6 for muscle. The ratio of COT-3 to
COT-2 varied from 9.8 for lung to 1.2 for pancreas.
Determination of the Transcription Start Site of the Human COT
Gene--
The transcription start site of the COT gene was
delimited by RT-PCR analysis to a 30-nt region (data not shown). The
exact transcription start site of the COT gene was
determined by primer extension on poly(A)+ RNA from
stimulated Jurkat cells with a primer complementary to primer 1D (PE
primer). This sequence is complementary to the three COT
transcripts. As shown in Fig. 2, a single
product corresponding to a 140-base extended fragment was detected. The
first transcribed base has been designated +1, to facilitate
numbering of the different COT transcripts. Sequence
analysis revealed a putative TATA box located at position 20 nt
(Figs. 2 and 3A), which is in
agreement with the preferred position occupied by this element in a
typical eukaryotic promoter (26).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 2.
Determination of the transcription start site
of the human COT gene. A, a
32P end-labeled primer complementary to nt 123-140 of
human COT cDNAs was annealed to poly(A)+ RNA
of Jurkat cells stimulated for 6 h with PDBu (50 ng/ml) and
calcium ionophore A23187 (0.25 µM) (lane 2) or
to poly(A)+ RNA from Dictyostelium
discoideum (lane 1) and extended with reverse
transcriptase. The products were analyzed in parallel with sequencing
reactions (ACGT) carried out on a genomic PCR product using
the same primer. The arrow shows the position of
the extended product. The sequences of the sense strand near the band
and the TATA box are shown below.
|
|

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 3.
Nucleotide sequence and putative regulatory
elements of the 5' flanking region of the human COT
gene and determination of its transcriptional activity.
A, the sequence is numbered relative to the transcription
start site, which is referred to as +1. The putative regulatory
elements are indicated in bold letters below
underlined sequences. B, Jurkat cells
were transfected with the pGL3, pGL3-778 (5'-3'), pGL3-778 , and
pGL3-778 (3'-5') constructs (20 µg/0.8 ml). The graph shows the
value of LRU/mg of protein (prot.) performed three
times in duplicate. A schematic representation of the different
constructs is also shown. The nomenclature of the different constructs
is denoted relative to the transcription initiation site (position
+1).
|
|
To confirm that the DNA region 5' flanking the defined transcription
start site of the human COT gene has promoter activity, transient expression experiments with the pGL3-Luc basic vector linked
to different fragments of this DNA region were carried out. Jurkat
cells were transfected with pGL3, pGL3-778 (5'-3'), and
pGL3-778 as well as with the pGL3-778 (3'-5') construct, and
luciferase activity was measured (Fig. 3B). The pGL3-778
(5'-3') construct, containing nt 778 to +115 of the COT
gene, exhibited a transcriptional activity 20-fold higher than that of
the empty pGL3 vector. The 30 to +115-nt region is essential in
maintaining this increase, because deletion of the 30 to +115-nt
fragment, in the pGL3-778 construct, resulted in transcriptional
activity similar to pGL3. No promoter activity over background levels
was detected with the pGL3-778 (3'-5') construct, indicating that this
region contains the transcription start site of the COT gene and not only cis-response elements.
Regulation of Human COT Promoter Activity by T
Cell-Regulating Signals--
To further study the
transcriptional activity of the 5' flanking region of the
COT gene, transient expression experiments were conducted in
Jurkat cells with pGL3 plasmids containing 1082 bp of the
COT gene 5' flanking region (Figs. 3 and
4A) as well as 5' deletion
fragments (Fig. 4A).

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 4.
Regulation of the human COT
promoter-luciferase construct activity by T cell stimulatory
signals. A, a schematic representation of the
COT promoter-based reported gene constructs. B,
Jurkat cells were transfected with the different constructs and 2 h later were stimulated or not with PDBu (50 ng/ml) and calcium
ionophore A23187 (0.25 µM) or with PDBu (50 ng/ml) and
soluble CD3 (10 µg/ml). The graph shows the mean of fold induction
of four different experiments performed in duplicate. A value of 1 was
given to that obtained with the basic COT promoter
(pGL3-102) under no stimulation conditions. C, Jurkat cells
were transiently transfected with the pGL3-340 (15 µg) or pGL3-778
(15 µg) constructs together with psc DN-SEK-2 (10 µg) or with
empty vector (10 µg), and cells were stimulated with PDBu (50 ng/ml)
and calcium ionophore A23187 (0.25 µM) or with PDBu (50 ng/ml) and soluble CD3 (10 µg/ml). The graph shows the mean of the
LRU/mg of protein (prot.) values of three
experiments performed in triplicate. D, cells were
transfected with pGL3-340 COT promoter construct and
activated with calcium ionophore A23187 and/or PDBu. Cyclosporin A (100 ng/ml), MEK inhibitor (MEK I, 20 µg/ml), HOG
inhibitor (HOG I, 20 µg/ml), okadaic acid (Oka,
100 ng/ml), and 8-Br-cAMP (cAMP, 0.5 mM) were
added to the incubation media 30 min prior to activation with
calcium ionophore A23187 (0.25 µM) and PDBu (50 ng/ml).
The graph shows the mean fold induction of four experiments performed
in duplicate.
|
|
Comparison of the relative promoter activities of the different
constructs indicated that the progressive removal of 5' sequences up to
650 did not significantly affect the COT promoter activity in unstimulated cells (Fig. 4B). Deletion of the 466 to
650 DNA fragment significantly decreased the transcriptional
activity. Further deletion of nt 340 to 229 further decreased the
activity of the COT promoter (Fig. 4B). However,
the pGL3-229 and pGL3-102 constructs still exhibited a
transcriptional activity 7-fold higher than vector pGL3 (data not shown).
To determine whether COT promoter activity is regulated by T
cell-activating signals, Jurkat cells were transfected with the different COT promoter-derived constructs and stimulated
with PDBu (50 ng/ml) and calcium ionophore (0.25 µM) or
with CD3 (10 µg/ml) and PDBu (50 ng/ml). Comparison of the
luciferase activities produced by each different plasmid in
unstimulated and stimulated cells showed that deletion of the sequences
located between positions 1082 to 340 did not significantly affect
the 3-fold induction relative to the unstimulated activity of each
construct. Further removal of the sequences from position 340 to
229 abolished the 3-fold induction by these signals (Fig.
4B).
One AP-1 binding site (27, 28) is found at position 327 nt of the 5'
flanking region of the COT gene (Fig. 3A). The
AP-1 transcription factor is up-regulated in T lymphocytes activated with PDBu and calcium ionophore or with CD3 and PDBu, and the JNK/SAPK signal transduction pathway mediates its activation. To
determine whether this signal transduction pathway regulates, at least
in part, activation of the COT promoter, Jurkat cells were
cotransfected with pGL3-340 or pGL3-788 together with the dominant
negative form of JNK kinase, DN-SEK-2 (MKK7-KL), that inhibits the
activation of c-Jun. Cells were stimulated or not with PDBu (50 ng/ml)
and calcium ionophore (0.25 µM) or with CD3 (10 µg/ml) and PDBu (50 ng/ml). As shown in Fig. 4C, the
expression of the DN-SEK-2 abolished the increase of the
promoter-driven transcription of the pGL3-340 and pGL3-778 constructs
by T-cell activating signals.
To further analyze the signal transduction mechanism by which the
COT promoter is activated, transient transfection
experiments with the pGL3-340 construct were performed. Addition of
PDBu or calcium ionophore by itself did not increase the luciferase
activity, indicating that an integration of both signals has to occur
to activate COT promoter-driven transcription (Fig.
4D). Transfected cells were also incubated with different
inhibitors or activators of protein kinases or protein phosphatases.
The transfected cells were incubated with PDBu (50 ng/ml) and calcium
ionophore (0.25 µM) in the presence or absence of
cyclosporin A (100 ng/ml), MEK inhibitor (20 µM), HOG
inhibitor (20 µM), okadaic acid (100 ng/ml), or 8-Br-cAMP
(0.5 mM) at doses that have already been reported to
regulate the activation of Jurkat T cells (9). Because addition of PDBu
and calcium ionophore to Jurkat T cells increases the phosphorylation
state of many proteins involved in the signal transduction mechanism,
the addition of okadaic acid, an inhibitor of protein phosphatases 1 and 2A, to these activated Jurkat cells could induce a further increase
in the phosphorylation state of the proteins. According to the results
obtained in Fig. 4D, the addition of okadaic acid did not
increase the luciferase activity. Addition of cyclosporin A prior to
activation of the cells reduced the luciferase activity, indicating
that calcineurin (protein phosphatase 2B) is at least partially
involved in the activation of the COT promoter. MEK
inhibitor, which blocks the ERK signal pathway, and HOG/p38
mitogen-activated protein kinase inhibitor hardly diminished the
stimulatory signal of PDBu and calcium ionophore. Activation of
cAMP-dependent protein kinase by the addition of 8-Br-cAMP increased the luciferase activity by about 1.7-fold (Fig.
4D).
Up-regulation of COT mRNA Levels--
An RNase protection
assay was performed to determine whether the increase in the
transcriptional activation of the 5' flanking region of the human
COT gene by T cell activating signals correlates with an
increase in COT mRNA levels after T lymphocyte
stimulation. A riboprobe from the COT coding sequence was
hybridized with RNA isolated from Jurkat cells stimulated with soluble
CD3 (10 µg/ml) and PDBu (50 ng/ml) for different times. As shown
in Fig. 5A, CD3 and PDBu
stimulation transiently increased COT mRNA levels (~4-fold). A similar increase in the level of COT
transcripts was detected by RT-PCR analysis of mRNA of Jurkat cells
stimulated with PDBu and calcium ionophore for different times, using
primers that amplified a COT coding sequence fragment. As a
control, a 187-bp fragment of -actin was also amplified in each
reaction (Fig. 5B).

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 5.
Induction of total COT
mRNA levels after Jurkat T cell activation.
A, RNase A protection analysis of COT mRNA
levels in Jurkat cells stimulated with PDBu (50 ng/ml) and CD3 (10 µg/ml). RNAs from Jurkat cells stimulated for different times from
Saccharomyces cerevisiae (Y) and
D. discoideum (D. d.) were used for the RNase
protection assay, using COT and -actin fragments as probes.
Undigested probes (U.P1 and U.P2) were also
electrophoresed. The histogram represents the relative value of
dividing the absorbance of the COT Rnase-protected product by the
absorbance of the -actin ( -Act) Rnase-protected
product at the indicated time. B, quantitative RT-PCR
analysis of the total COT mRNA of Jurkat cells
stimulated for different times with calcium ionophore A 23187 (0.25 µM) and PDBu (50 ng/ml). PCRs were performed with primers
9D (1 µM) and 8R (1 µM) and -actin
primers (0.1 µM) ( -actin product, 187 bp). The figure
shows one of the three experiments performed. The histogram represents
the relative value of dividing the absorbance of the COT PCR product by
absorbance of the -actin PCR product at the indicated time,
expressed as the mean ± S.D. from three different
experiments.
|
|
To distinguish COT-1 from COT-2 and
COT-3, a Northern blot with total RNA from Jurkat
cells stimulated for different times with PDBu (50 ng/ml), calcium
ionophore (0.25 µM), and okadaic acid (100 nM) was hybridized with the coding COT probe
(Fig. 6A). Whereas a
hybridization signal of 3.0 kb, corresponding to COT-2 and
COT-3, was detected 3 h after stimulation, the
COT-1 message was first detected 6 h after stimulation.
In agreement with the Northern blot analysis, COT-1
transcript levels determined by RT-PCR were not increased at 4 h
after stimulation of Jurkat cells with the stimuli described above
(Fig. 6B). At this time of stimulation, COT-2 and
COT-3 levels were increased to an equal extent (Fig. 6B).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 6.
Induction of COT-1,
COT-2, and COT-3 mRNA levels in
activated Jurkat cells. A, Northern blot analysis of
the kinetics of induction of COT mRNAs isolated from
Jurkat cells stimulated with PDBu (50 ng/ml), calcium ionophore (0.25 µM), and 100 nM okadaic acid, using the
coding sequence of COT kinase as a probe. Quantification of the RNA
loading was performed by methylene blue staining of the membranes after
transfer for detection of the 28 S and 18 S RNAs. B, RT-PCRs
from RNA of Jurkat cells stimulated for 4 h with the stimuli
(St) described above or not (C). The PCRs were
performed with the different COT primers indicated in the
diagrams, at a concentration of 1 µM. In each reaction
tube a  actin fragment was also amplified using primers at a final
concentration of 0.1 µM. The figures show one
representative experiment of the four performed. The histogram
represents the relative value of dividing the absorbance of the COT-1,
COT-2, and COT-3 PCR products by the absorbance of the -actin
( -Act) PCR product, expressed as the mean ± S.D. of
the four different experiments.
|
|
Subcellular Distribution of COT Transcripts--
Next, we decided
to investigate the subcellular distribution of COT-1,
COT-2, and COT-3. RNA was isolated from
the cytoplasmic fraction and the nuclear fraction of intact Jurkat
cells. A dot blot performed with these RNAs was hybridized with a probe
specific for the 5' UTR of COT-1 (probe C), the
COT coding probe, and a probe containing the 778 to 30
nt sequence of the COT promoter (Fig.
7A). Comparison of the
hybridization signals obtained with the different probes and RNA
fractions indicated that the COT-1 transcript is mainly
located in the nuclear fraction.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 7.
Distribution of COT
transcripts. A, a dot blot performed with total
RNA, RNA isolated from the cytoplasmic fraction, and RNA isolated from
the nuclear fraction was hybridized with probe C (nt 3837-4646), the
COT coding probe, and a probe generated from the
COT promoter region (nt 778 to 30). B,
distribution of COT transcripts in polysomes. The
figure shows the relative absorbance corresponding to the different
sucrose fractions. The 28 S and 18 S RNAs from 6 µl of each
fraction were separated on a 2.2 M formaldehyde-agarose
denaturing gel and photographed after ethidium bromide staining. RT-PCR
analysis of the different fractions was performed. COT-1
levels were determined with primers 8D (1 µM) and 8R (1 µM), COT-2 levels were determined with primers 6D (1 µM) and 7R (1 µM), and COT-3 levels were
determined with primers 1D (1 µM) and 7R (1 µM). Primers for -actin detection were used at a
concentration of 0.1 µM.
|
|
We next decided to study the distribution of the different
COT messengers to polysomes. The postmitochondrial
supernatant of Jurkat cells was subjected to sucrose gradient
fractionation, and RNA was isolated from the different fractions. The
levels of the different COT transcripts were measured by
RT-PCR analysis. As shown in Fig. 7B, the fraction of
COT-1 located in the cytoplasmic fraction is not associated
with polysomes. In addition, only a small fraction of COT-2
was not loaded with ribosomes. The fact that both COT-2 and
COT-3 were detected in fractions corresponding to
small polysomes indicates a low translation efficiency of these transcripts. As a control of polyribosome-associated mRNA, we assayed the same fractions for -actin messenger (Fig.
7B). Stimulation of Jurkat cells with PDBu and calcium
ionophore did not change the distribution of these transcripts in the
different fractions (data not shown).
 |
DISCUSSION |
In this paper we have identified the promoter region of the human
COT gene and demonstrated that its activity is inducible by
T cell-activating signals. We have also identified three different human COT mRNAs, COT-1, COT-2, and
COT-3, with different lengths in the 5'UTR but a
common transcription initiation site. This site is located 4748 nt
upstream of the translation initiation site of COT kinase. The first
exon of COT-1 (denominated exon 1) comprises these 4748 nt
and the first 336 nt of the coding sequence of COT kinase (see Table I
and Fig. 1). The lack of splicing in the 5'UTR of COT-1
mRNA species results in a predominantly nuclear distribution. The
physiological significance of this finding remains to be established.
Nevertheless, the possibility that COT-1 mRNA is stored
in the cell nucleus and a later processing of its 5' UTR triggers the
transport of the generated transcript to the cytoplasm should not be
excluded. A similar situation has been described for other mRNAs
(29). The 5' UTR of the COT-2 transcript is
generated when the 5' region flanking the translation initiation site
of human COT kinase undergoes splicing, and this UTR comprised
of exons 1a, 1b, and 1c. This 5' UTR contains 444 nt upstream
of the coding sequence of COT kinase and exhibits a putative
open reading frame located in exon 1b. COT-3 mRNA, with a 215-nt 5' UTR, is comprised of exons 1a and 1c and does not have
any open reading frame upstream of the translation initiation site of
COT kinase. The occurrence of upstream open reading frames has only
been detected in about 10% of vertebrate mRNAs, and their physiological role is still unclear. Interestingly, the majority of
these mRNA species code for proteins involved in signal
transduction (30, 31 and references therein).
Toyoshimo and co-workers (15, 17) reported a genomic structure of the
human COT gene with 9 exons, from which the 2 upstream exons
are noncoding, and defined a 5' UTR of the COT transcript (GenBankTM accession number D14497) with 366 nt;
this sequence corresponds to part of the 5' UTR of the COT-2
transcript defined here. Chan et al. (14) reported a
COT transcript (GenBankTM accession number
Z14138) (denominated est in their study) with a
159-nt long 5' UTR; this sequence corresponds to part of the 5' UTR of COT-1 defined here.
It has recently been reported that an increase in COT
mRNA levels, determined by RT-PCR analysis, of a 136-nt fragment of the COT coding sequence plays a role in human breast cancer
(22). Based on the data obtained here, demonstration of this role in tumorigenesis would require analysis of the expression of the different
COT transcripts in tumoral versus normal tissues,
because the study of the subcellular and polysome distribution of the different COT transcripts indicates that COT-1 is not
attached to polysomes but is mainly located in the nucleus and is,
therefore, probably not translated.
We did not find any evidence of additional splicing variants in the
protein coding exons of the described human COT gene (data not shown). This is probably because COT kinase does not have any of
the known signaling modules, and consequently changes in the coding
sequence (with the exception of the last exon) would result in the
modification of at least one of the XI regions necessary for a
functional protein kinase (32). Deletion of the last exon provides
transformation capacity to COT kinase (4, 15, 20, 21).
The COT gene is induced during T cell activation. Both
combinations of stimuli (PDBu and calcium ionophore or PDBu and CD3) induce an increase in COT mRNA levels as well as
activation of the COT promoter-driven transcription. A
number of consensus sequences reported to bind specific trans-acting
factors regulated by activating T signals are present in the 5'
flanking region of the COT gene (Fig. 3). Thus, three AP-1
binding sites (27, 28) were found at positions 79, 327, and 637
nt. One PEA-3 motif (33) was located at 267 nt. The analysis
also revealed one consensus recognition motif for ets (34) at position
808 nt and four consensus binding sequences for OCT-1 (35) at
positions 293, 501, 708, and 1037 nt. The ets and OCT-1
response elements have been reported to be regulated by phorbol esters
(36). Two cAMP-response element (CRE)-like sequences (36) are
found at positions 41 and 164 nt, which could account for the
increased COT promoter activity observed upon 8-Br-cAMP
treatment. This finding also suggests that different signal
transduction pathways can mediate COT regulation. The relative activities of the different COT promoter
constructs in the presence and absence of T cell activating signals
indicated that a PDBu and calcium ionophore response element is located in the 340 to 229-nt region of the COT promoter.
Activation of the AP-1 response elements in T cells requires an
integration of both PDBu and calcium ionophore signals, is independent
of ERK pathway activation, is sensitive to cyclosporin A, and is up-regulated by the JNK/SAPK signal transduction pathway (9, 37). The same requirements are needed for activation of the 340
COT promoter-driven transcription, indicating that at least the AP-1 binding site present at 327 nt could play a role in the PDBu
and calcium ionophore-triggered COT promoter activation.
COT kinase activity is crucial for the transduction mechanism of
activating signals in T cells during G0/G1
transition (1, 8-12). The data presented here indicate that the
expression of the COT gene is regulated by these same signals.
 |
ACKNOWLEDGEMENTS |
We thank Luis Alvarez Querido and Jose
Gonzalez Castaño for critical reading of the manuscript,
Joaquin Perez for technical assistance, Drs. Manolo Fresno and Tadashi
Nishida for the pSC DN-SEK-2 construct, and Dr. A. Arnero (Sandoz-España) for providing cyclosporin A.
 |
FOOTNOTES |
*
This work was supported by Plan Nacional, Comunidad de
Madrid, and Europharma.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF133211.
Both authors contributed equally to this work.
¶
To whom correspondence should be addressed: Tel.:
34-91-3975445; Fax: 34-91-5854587; E-mail:
salemany@biomed.iib.uam.es.
Published, JBC Papers in Press, July 13, 2000, DOI 10.1074/jbc.M000382200
 |
ABBREVIATIONS |
The abbreviations used are:
MEK-1, mitogen-activated protein kinase kinase-1;
SEK-1, mitogen-activated
protein kinase kinase-4;
ERK, extracellular signal-regulated kinase;
JNK, c-Jun NH2-terminal kinase;
SAPK, stress-activated
protein kinase;
UTR, untranslated region;
nt, nucleotide(s);
kb, kilobase(s);
PCR, polymerase chain reaction;
PDBu, phorbol
12,13-dibutyrate;
8-Br-cAMP, 8-bromoadenosine 3':5'-cyclic
monophosphate;
RT, reverse transcription;
bp, base pair(s).
 |
REFERENCES |
| 1.
|
Salmerón, A.,
Ahmad, T. B.,
Carlille, G. W.,
Pappin, D.,
Narsimham, R. P.,
and Ley, S. C.
(1996)
EMBO J.
15,
817-826
|
| 2.
|
Fanger, G. R.,
Gerwins, P.,
Widmann, C.,
Jarpe, M. B.,
and Johnson, G. L.
(1997)
Curr. Opin. Genet. Dev.
7,
67-74
|
| 3.
|
Hunter, T.
(1997)
Cell
88,
333-346
|
| 4.
|
Patriotis, C.,
Makris, A.,
Bear, S. E.,
and Tsichlis, P. N.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
2251-2255
|
| 5.
|
Robinson, M. J.,
and Cobb, M. H.
(1997)
Curr. Opin. Cell Biol.
9,
180-186
|
| 6.
|
Patriotis, C.,
Makris, A. M.,
Chernoff, J.,
and Tsichlis, P. N.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
9755-9759
|
| 7.
|
Troppmair, J.,
Bruder, J. T.,
Munoz, H.,
Lloyd, P. A.,
Kyriakis, J.,
Banerjee, P.,
Avruch, J.,
and Rapp, U. R.
(1994)
J. Biol. Chem.
269,
7030-7035
|
| 8.
|
Ballester, A.,
Calvo, V.,
Tobeña, R.,
Lisbona, C.,
and Alemany, S.
(1997)
J. Immunol.
159,
1613-1618
|
| 9.
|
Ballester, A.,
Velasco, A.,
Tobeña, R.,
and Alemany, S.
(1998)
J. Biol. Chem.
273,
14099-14106
|
| 10.
|
Tsatsanis, C.,
Patriotis, C.,
and Tsichlis, P. N.
(1998)
Oncogene
19,
2609-2618
|
| 11.
|
Tsatsanis, C.,
Patriotis, C.,
Bear, S. E.,
and Tsichlis, P. N.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
3827-3832
|
| 12.
|
Belich, M. P.,
Salmerón, A.,
Johnston, L. H.,
and Ley, S. C.
(1999)
Nature
397,
363-368
|
| 13.
|
Lin, X.,
Cunningham, E. T., Jr.,
Mu, Y.,
Geleziunas, R.,
and Greene, W. C.
(1999)
Immunity
10,
271-280
|
| 14.
|
Chan, A. M-L.,
Chedid, M.,
McGovern, E. S.,
Popescu, N. C.,
Miki, T.,
and Aaronson, S. A.
(1993)
Oncogene
8,
1329-1333
|
| 15.
|
Aoki, M.,
Hamada, F.,
Sugimoto, T.,
Sumida, S.,
Akiyama, T.,
and Toyoshima, K.
(1993)
J. Biol. Chem.
268,
22723-22731
|
| 16.
|
Makris, A.,
Patriotis, C.,
Bear, S. E,
and Tsichlis, P. N.
(1993)
J. Virol.
67,
4283-4289
|
| 17.
|
Ohara, R.,
Miyoshi, J.,
Aoki, M.,
and Toyoshima, K.
(1993)
Jpn. J. Cancer Res.
84,
518-525
|
| 18.
|
Miyoshi, J.,
Higashi, T.,
Mukai, H.,
Ohuchi, T.,
and Kakunaga, T.
(1991)
Mol. Cell. Biol.
11,
4088-4096
|
| 19.
|
Aoki, M.,
Akiyama, T.,
Miyoshi, J.,
and Toyoshima, K.
(1991)
Oncogene
6,
1515-1519
|
| 20.
|
Erny, K. M.,
Peli, J.,
Lambert, J-F.,
Muller, V.,
and Diggelmann, H.
(1996)
Oncogene
13,
2015-2020
|
| 21.
|
Ceci, J. D.,
Patriotis, C. P.,
Tsatsanis, C.,
Makris, A. M.,
Kovatch, R.,
Swing, D. A.,
Jenkins, N. A.,
Tsichlis, P. N.,
and Copeland, N. G.
(1997)
Genes Dev.
11,
688-700
|
| 22.
|
Sourvinos, G.,
Tsatsanis, D. A.,
and Spandidos, D. A.
(1999)
Oncogene
18,
4968-4973
|
| 23.
|
Blin, N.,
and Stafford, D. V.
(1976)
Nucleic Acids Res.
3,
2303-2308
|
| 24.
|
Sanger, F.,
Niksen, S.,
and Coulson, A. R.
(1977)
Proc. Natl. Acad. Sci. U. S. A.
74,
5463-5467
|
| 25.
|
Nakiely, S.,
and Dreyfuss, G.
(1997)
Curr. Opin. Cell Biol.
9,
420-429
|
| 26.
|
Bucher, P.
(1990)
J. Mol. Biol.
212,
563-578
|
| 27.
|
Angel, P.,
Imagawa, M.,
Chiu, R.,
Stein, B.,
Imbra, R.,
Rahmsdorf, H. J.,
Jonat, C.,
Herrlich, P.,
and Karin, M.
(1987)
Cell
49,
729-739
|
| 28.
|
Lee, W.,
Mitchell, P.,
and Tjian, R.
(1987)
Cell
49,
741-752
|
| 29.
|
Weil, D.,
Brosset, S.,
and Dautry, F.
(1990)
Mol. Cell. Biol.
10,
5865-5875
|
| 30.
|
Jackson, R. J.,
and Wickens, M.
(1997)
Curr. Opin. Genet. Dev.
7,
233-239
|
| 31.
|
Kozak, M.
(1999)
Gene
234,
187-208
|
| 32.
|
Hanks, S. K.,
Quinn, A. M.,
and Hunter, T.
(1988)
Science
241,
42-52
|
| 33.
|
Martin, M. E.,
Piette, J.,
Yaniv, M.,
Tang, W. J.,
and Folk, W. R.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
5839-5843
|
| 34.
|
Macleod, K.,
Leprince, D.,
and Stehelin, D.
(1992)
Trends Biochem. Sci.
17,
251-256
|
| 35.
|
Ho, C.,
Bhat, N. K.,
Gottschalk, L. R.,
Lindsten, R.,
Thompson, C. B.,
Papas, T. S.,
and Leiden, J. M.
(1990)
Science
250,
814-818
|
| 36.
|
Faisst, S.,
and Meyer, S.
(1992)
Nucleic Acids Res.
20,
3-26
|
| 37.
|
Su, B.,
Jacinto, E.,
Hibi, M.,
Karin, M.,
and Ben-Neriah, Y.
(1994)
Cell
77,
726-736
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
P. E. Kovanen, J. Bernard, A. Al-Shami, C. Liu, J. Bollenbacher-Reilley, L. Young, C. Pise-Masison, R. Spolski, and W. J. Leonard
T-cell Development and Function Are Modulated by Dual Specificity Phosphatase DUSP5
J. Biol. Chem.,
June 20, 2008;
283(25):
17362 - 17369.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Caivano, C. Rodriguez, P. Cohen, and S. Alemany
15-Deoxy-{Delta}12,14-prostaglandin J2 Regulates Endogenous Cot MAPK Kinase Kinase 1 Activity Induced by Lipopolysaccharide
J. Biol. Chem.,
December 26, 2003;
278(52):
52124 - 52130.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. L. Channavajhala, L. Wu, J. W. Cuozzo, J. P. Hall, W. Liu, L.-L. Lin, and Y. Zhang
Identification of a Novel Human Kinase Supporter of Ras (hKSR-2) That Functions as a Negative Regulator of Cot (Tpl2) Signaling
J. Biol. Chem.,
November 21, 2003;
278(47):
47089 - 47097.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|